Payment overview · 2025
General Payments
$585.59
30 reported records · 8 companies
Healthcare provider profile · identity verified
Anna Seay, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1821435207
Verified facts
What the public records show
CMS Open Payments records show Anna Seay, M.D. received $585.59 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $317.03 | 54.1% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.07 | 17.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.73 | 8.5% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $31.36 | 5.4% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $28.00 | 4.8% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $27.06 | 4.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $19.35 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.99 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $585.59 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $262.19 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $209.36 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.97 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.73 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.73 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.58 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| FIBRYGA Normalized: fibryga |
Biological | Octapharma USA, Inc. | $28.00 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
180 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 503 | 163 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 75 |
| Omeprazole | Omeprazole | 245 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 228 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 65 |
| Lisinopril | Lisinopril | 203 | 65 |
| Metformin Hcl | Metformin Hcl | 182 | 58 |
| Ozempic | Semaglutide | 180 | 39 |
| Gabapentin | Gabapentin | 171 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 55 |
| Trazodone Hcl | Trazodone Hcl | 157 | 44 |
| Tramadol Hcl | Tramadol Hcl | 147 | 37 |
| Meloxicam | Meloxicam | 135 | 48 |
| Losartan Potassium | Losartan Potassium | 122 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 37 |
| Ezetimibe | Ezetimibe | 104 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 27 |
| Furosemide | Furosemide | 88 | 28 |
| Potassium Chloride | Potassium Chloride | 81 | 33 |
| Famotidine | Famotidine | 79 | 30 |
| Buspirone Hcl | Buspirone Hcl | 78 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 22 |
| Temazepam | Temazepam | 74 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 30 |
| Memantine Hcl | Memantine Hcl | 70 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 20 |
| Allopurinol | Allopurinol | 66 | 21 |
| Montelukast Sodium | Montelukast Sodium | 64 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 18 |
| Sertraline Hcl | Sertraline Hcl | 61 | 18 |
| Carvedilol | Carvedilol | 60 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | 19 |
| Alendronate Sodium | Alendronate Sodium | 57 | 17 |
| Celecoxib | Celecoxib | 57 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 17 |
| Simvastatin | Simvastatin | 52 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | 12 |
| Jardiance | Empagliflozin | 47 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 16 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | 17 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 15 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 13 |
| Methylprednisolone | Methylprednisolone | 36 | 33 |
| Ondansetron Odt | Ondansetron | 36 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 11 |
| Mirtazapine | Mirtazapine | 32 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 15 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Prednisone | Prednisone | 20 | 11 |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Ampicillin Sodium | Ampicillin Sodium | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Zolmitriptan | Zolmitriptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $585.59 · 30 records | ABBVIE INC. | FIBRYGA, INJECTAFER, MOUNJARO, Omnipod, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error